Basic Bimat + Applicators Information

• INN (International Nonproprietary Name): Bimatoprost
• Brand Names Available In United States: Latisse (0.03% eyelash solution with single‑use applicators), Lumigan (0.01%/0.03% ophthalmic solution), Durysta (intracameral implant for glaucoma).
• ATC Code: S01EE03
• Forms & Dosages: Ophthalmic solution 0.03% for eyelash hypotrichosis (Latisse, 3 mL/5 mL with ~60+ applicators); Lumigan available in 0.01% and 0.03% bottles (various volumes); some generics (Careprost/Bimat) commonly as 0.03% 3 mL or 5 mL.
• Manufacturers In United States: Allergan/AbbVie (Latisse/Lumigan), Mylan, Sandoz (generics).
• Registration Status In United States: Prescription-only (FDA-approved for eyelash hypotrichosis and for glaucoma/ocular hypertension).
• OTC / Rx Classification: Prescription Only (Rx) — local regulations may vary for look‑alike cosmetic serums in other countries.

Everyday Use And Best Practices

Morning Vs Evening Dosing

Many patients ask whether to use bimatoprost in the morning or at night.

The approved eyelash regimen is one drop of 0.03% bimatoprost ophthalmic solution to the upper eyelid margin once nightly using a sterile single‑use applicator.

Nightly application is the standard for eyelash growth and improves absorption at the lash line while reducing daytime transfer during activity.

For glaucoma dosing, single daily application may be morning or evening, but for lashes the product labeled for hypotrichosis is applied at night only.

Do not apply more often than instructed since doubling doses does not accelerate results and increases the risk of irritation.

Careful timing and technique protect the eyelid skin and reduce unwanted spread of product to nearby areas.

Taking With Or Without Meals

Topical bimatoprost ophthalmic solution has no meaningful food interactions for eyelash dosing.

The eyelash routine fits easily into nightly hygiene before bed.

Start by removing eye makeup and cleansing the face to reduce contamination of the applicator.

Dry the lids thoroughly before applying a small amount along the upper eyelid margin with the sterile applicator supplied.

Replace the cap tightly on the bottle and dispose of the applicator after a single use.

Store the product at 2–25°C (36–77°F) away from heat and light.

• Nightly Routine Checklist
• Cleanse face and remove eye makeup.
• Dry eyelids completely.
• Use one sterile single‑use applicator per eye and apply 0.03% bimatoprost along the upper eyelid margin once nightly.
• Dispose applicator immediately and re‑cap the bottle tightly.
• Store at 2–25°C and do not use after expiry.

Safety Priorities

Who Should Avoid It

Patients should avoid bimatoprost if they have a known hypersensitivity to bimatoprost or to excipients such as benzalkonium chloride.

Active ocular infections or inflammatory conditions are absolute contraindications.

Relative cautions include a history of uveitis or macular edema and aphakia or pseudophakia with a torn lens capsule.

Children are not recommended to use bimatoprost for cosmetic eyelash enhancement because safety and efficacy are not established for that indication.

Glaucoma use in children or other special populations should follow specialist guidance.

• Contraindications Checklist
• Known allergy to bimatoprost or preservatives (e.g., benzalkonium chloride).
• Active eye infection or inflammation.
• History of severe intraocular inflammatory disease, uveitis, or macular edema (exercise caution).
• Children for cosmetic eyelash use — avoid unless advised by a specialist.

Activities To Limit

Never share or reuse sterile single‑use applicators since reuse increases the risk of infection.

Avoid rubbing the eyes after application to limit spread and irritation.

Avoid swimming or sauna immediately after applying to prevent washout of the solution from the eyelid margin.

Stop use and seek ophthalmic review if marked redness, persistent irritation, new eye pain, or vision changes develop.

Risk	Recommended Activity Guidance
Sharing/Reuse Of Applicators	Do not share applicators; use single‑use sterile applicators only.
Eye Rubbing	Avoid rubbing after application to reduce spread and irritation.
Swimming/Sauna	Delay water exposure until the product has dried to prevent washout.
Irritation Or Vision Changes	Discontinue use and seek ophthalmic review immediately.

Dosage And Adjustments

General Regimen

The standard eyelash regimen is one drop of 0.03% bimatoprost ophthalmic solution applied to the upper eyelid margin once nightly using a sterile applicator per eye.

For glaucoma or ocular hypertension the regimen is one drop into the affected eye(s) once daily, either morning or evening but not both.

Use the sterile single‑use applicators included to control the amount and limit contamination.

Special Cases

There is no routine dose reduction required for elderly patients, though monitoring for ocular surface side effects is advised.

Limited data exist for patients with severe renal or hepatic impairment, so use caution and monitor if prescribed for ocular conditions.

Children are not recommended to use bimatoprost for cosmetic eyelash growth because safety and efficacy are unestablished.

Missed doses should be applied at the next usual time and never doubled to catch up.

In the event of accidental overdose or excess application, rinse the eyes with water and consult a clinician if excessive exposure is persistent.

Indication	Adult Dose
Eyelash Hypotrichosis	One drop 0.03% to the upper eyelid margin once nightly with sterile applicator per eye.
Glaucoma/Ocular Hypertension	One drop into affected eye(s) once daily (morning or evening, not both).

• Missed Dose / Overdose Checklist
• If a nightly application is missed, apply the next night; do not double the dose.
• If excess solution enters the eye, rinse with water and consult your prescriber if symptoms persist.

User Testimonials

Positive Reports

Users commonly report thicker, longer, and darker lashes beginning around four weeks, with optimal results typically near 16 weeks of nightly use.

Maintaining results requires continued application; stopping the product usually returns lashes to baseline over time.

Many positive anecdotes reference kits such as Latisse 3 mL or 5 mL that include about 60 sterile applicators for controlled nightly dosing.

Common Challenges

Some users experience transient eyelid irritation, redness, or itching that may resolve with continued use or after stopping the product.

Reports of darkening of the eyelid skin or iris exist, and iris pigmentation changes may be permanent even if treatment stops.

Misdirected lash growth or lashes extending beyond the treated area can occur if product is applied too liberally.

• Pros
• Noticeable lash length and fullness within 4–16 weeks with regular nightly application.
• Packaged kits with sterile applicators help maintain hygiene and dosing accuracy.

• Cons
• Possible eyelid or ocular irritation.
• Risk of skin or iris pigmentation changes; iris change may be permanent.
• Needs ongoing use to sustain cosmetic effect.

"I saw a difference around week six and full results by month four after following the nightly routine with the applicators."

"A bit of stinging at first, but it settled; I kept a photo log to compare progress."

"One applicator per eye and careful application prevented spillover onto my eyelid skin."

Buying Guide

Pharmacy Sources

Bimatoprost is prescription‑only in most markets including the USA, where Latisse and Lumigan are marketed by Allergan/AbbVie and generics are produced by Mylan and Sandoz.

Generics and branded generics such as Careprost, Bimat, or Bimatop often appear on international e‑shops labeled as 0.03% with bundled applicators in some regions.

Always check local regulation before purchasing and confirm whether a valid prescription is required.

In our online pharmacy, bimat + applicators is available without a prescription, with discreet delivery to United States in 5-14 days.

Price Comparison

Price varies by brand, concentration, and pack size.

Latisse 0.03% commonly comes as 3 mL or 5 mL packs with ~60+ applicators and is typically more expensive than generics.

Lumigan is sold at 0.01% and 0.03% concentrations in a range of bottle sizes, with generics usually offering a lower price point.

Factor in the number of included applicators, shipping fees, and whether a prescription is required when comparing total cost.

Brand	Concentration	Pack Size	Estimated Price Range
Latisse	0.03%	3 mL, 5 mL with ~60+ applicators	Higher (branded price; varies by pharmacy and insurance)
Lumigan	0.01%, 0.03%	2.5 mL, 3 mL, 5 mL, larger bottles	Moderate (generics often available)
Careprost / Bimat	0.03%	3 mL, 5 mL (often bundled with applicators)	Lower (varies by region and seller)

What’s Inside And How It Works

Ingredients Overview

The active ingredient is bimatoprost, typically at 0.03% for eyelash hypotrichosis formulations such as Latisse.

Excipients vary by manufacturer and some formulations contain preservatives such as benzalkonium chloride.

Products marketed for eyelash growth are commonly supplied with sterile single‑use applicators to control dosing and prevent contamination.

Mechanism Basics

Bimatoprost is classified as a prostaglandin analogue in the ATC group S01EE03.

It stimulates hair growth by prolonging the anagen (growth) phase of the hair cycle and can increase eyelash pigmentation and thickness.

For glaucoma, bimatoprost lowers intraocular pressure by increasing uveoscleral outflow.

Patients should be counseled that iris pigmentation changes can occur and may be permanent.

• Key Ingredients
• Bimatoprost 0.03% (active).
• Preservatives (may include benzalkonium chloride) and other excipients varying by brand.
• Sterile single‑use applicators included in most eyelash kits.

Mechanism	Indication
Prolongs anagen phase; increases pigmentation and thickness of lashes	Eyelash hypotrichosis (0.03% topical)
Increases uveoscleral outflow to lower IOP	Glaucoma / Ocular Hypertension

Main Indications

Approved Uses

The FDA in the United States has approved bimatoprost topical 0.03% for treatment of hypotrichosis of the eyelashes (marketed as Latisse).

Bimatoprost ophthalmic solutions such as Lumigan are approved for glaucoma and ocular hypertension.

Durysta is an intracameral bimatoprost implant approved for glaucoma in specific clinical contexts.

Off-Label Uses

Off‑label cosmetic applications include eyebrow enhancement or application outside the upper lash margin, but these lack robust regulatory approval and carry higher risks.

Applying product beyond the recommended area increases the chance of skin or unintended hair growth and pigment changes.

Use	Regulatory Note
Eyelash Hypotrichosis	FDA‑approved for bimatoprost 0.03% (Latisse) in the USA
Glaucoma / Ocular Hypertension	Approved (Lumigan and other formulations; Durysta implant for specific indications)
Brow Enhancement / Wider Cosmetic Use	Off‑label; not generally approved and may increase risk of pigmentation or misdirected hair growth

Interaction Warnings

Food Interactions

Topical ophthalmic bimatoprost has no known food interactions and meals do not affect eyelash dosing.

Systemic absorption from topical eyelid application is minimal for typical cosmetic use.

Drug Conflicts

Using multiple ocular hypotensive drops requires coordination with an ophthalmologist because functional interactions can occur and scheduling matters.

Avoid combining different prostaglandin analogues without clinician oversight.

Contact lens wearers should follow product instructions; lenses may need to be removed before administration and not reinserted for a specified period if advised by the product labeling or prescriber.

• Eye Product Interaction Checklist
• Inform your eye doctor about all topical eye medications to coordinate dosing.
• Avoid coadministration of other prostaglandin analogues without guidance.
• Follow contact lens guidance from the product label or prescriber.

• Contact Lens Guidance
• Remove soft contact lenses prior to administration if advised by the product instructions.
• Wait the instructed interval before reinserting lenses to avoid contamination or irritation.

Latest Evidence And Insights

Key Study Takeaways

Clinical data show lash improvements in length and thickness often begin by four weeks and reach optimal effect near 16 weeks with nightly 0.03% topical bimatoprost.

Sustained cosmetic benefit requires continued use; stopping treatment typically reverses gains over time.

Many comparative studies focus on intraocular pressure effects rather than cosmetic outcomes when comparing bimatoprost to other prostaglandins.

Practical Clinical Notes

Monitor patients for periocular pigmentation and ocular surface irritation during follow‑up appointments.

For glaucoma patients, schedule regular intraocular pressure checks and ophthalmic follow up as part of standard care.

Counsel cosmetic users about prescription status, expected timeline to effect (4–16 weeks), and the potential permanence of some pigment changes.

Parameter	Typical Finding
Time to Initial Effect	About 4 weeks
Time to Optimal Effect	Approximately 16 weeks
Common Adverse Events	Irritation, eyelid/iris pigmentation, eyelash misdirection

• Clinician Monitoring Checklist
• Baseline assessment of ocular surface and iris color.
• Follow‑up at intervals to assess irritation and pigmentation.
• IOP checks for glaucoma patients as clinically indicated.

Alternative Choices

Prescription Alternatives

Other prostaglandin analogues such as latanoprost, travoprost, and tafluprost are primarily indicated for glaucoma and have occasional reports of lash effects but are not FDA‑labeled for eyelash hypotrichosis in the United States.

For patients seeking a prescription‑labelled option for lashes, Latisse (bimatoprost 0.03%) remains the approved choice.

Over-The-Counter Options

OTC eyelash serums often contain peptides, vitamins, or botanical extracts and have weaker clinical evidence compared with bimatoprost for producing meaningful lash growth.

OTC serums may be considered by users who prefer to avoid prostaglandin analogue risks, while understanding that results are usually more modest.

Option	Efficacy	Safety	Cost
Prescription Bimatoprost (Latisse)	High (supported by clinical data)	Requires monitoring for pigmentation/irritation	Moderate–High
Other Prostaglandin Analogues (Off‑label)	Variable; not labeled for lashes	Similar ocular safety considerations	Variable
OTC Serums (Peptides, Botanicals)	Lower; limited clinical evidence	Generally well tolerated; watch for skin reactions	Low–Moderate

Regulation Snapshot

Global Regulatory Status

Bimatoprost is prescription‑only in most countries.

In the United States the FDA has approved bimatoprost for eyelash hypotrichosis (Latisse) and for glaucoma/OHT (Lumigan and Durysta implants for specific indications).

The European Union and other regions generally approve bimatoprost for glaucoma; eyelash indications vary by country.

In countries such as India and Russia, some products are commonly marketed online as “eyelash growth serum” with bundled applicators, but local regulation differs.

Packaging And Labeling Notes

Products intended for eyelash use typically list concentration and volume on the carton and include sterile single‑use applicators.

Common labeled volumes include Latisse 3 mL and 5 mL packages with applicators, and Lumigan bottles available in multiple sizes and concentrations.

• USA: Prescription required; Latisse and Lumigan are commonly available through prescribers and pharmacies.
• EU: Glaucoma indications widely approved; eyelash use varies by member state.
• India/Russia: Eyelash‑marketing e‑shop formulations and bundles are common; check local rules.

Brand	Region	Regulatory Status
Latisse	USA, Canada, EU	Approved for eyelash hypotrichosis (prescription)
Lumigan	Global	Approved for glaucoma/OHT (prescription)
Careprost / Bimat	India, Russia, Eastern EU	Commonly marketed for eyelash growth on e‑shops; local regulation varies

FAQ Section

Common Patient Questions

How long to see results?

Some users see initial change by about four weeks with more visible and optimal results around 16 weeks; continued use is required to maintain gains.

Can I reuse applicators?

No; applicators included with eyelash kits are sterile and single‑use only to prevent infection.

Is it safe long term?

For glaucoma, long‑term use under ophthalmic supervision is common; for cosmetic eyelash use, monitor for pigmentation and irritation and review with a prescriber if concerns arise.

Quick Answers And Troubleshooting

If irritation occurs, stop applying, rinse the area with water, and consult your prescriber or ophthalmologist.

If new pigment changes appear in the eyelid or iris, discontinue use and arrange ophthalmic follow up since iris changes may be permanent.

Store the product between 2–25°C and discard after the expiry date or if the solution changes color or clarity.

• Quick Troubleshooting Checklist
• Minor stinging or redness: pause use and monitor; seek advice if persistent.
• Severe pain or vision changes: stop use and seek urgent ophthalmic evaluation.
• Applicator contamination or reuse: discard and resume with a fresh sterile applicator.

Question	Quick Answer
How long to see results?	Initial effect ~4 weeks; optimal by ~16 weeks; ongoing use required.
Can I reuse applicators?	No; single‑use only.
Storage	Store at 2–25°C and keep cap tightly closed.

Guidelines For Proper Use

Step‑By‑Step Application

Many patients ask for a clear stepwise routine to avoid overapplication and spillover.

Begin by removing contact lenses if advised and cleansing the eyelids and face of makeup and oils.

Dry lids completely before application to allow controlled placement of the solution along the upper lash margin.

Use the sterile single‑use applicator supplied with the kit to take a small amount of 0.03% bimatoprost and apply a thin line to the upper eyelid margin once nightly.

Use one applicator per eye and dispose immediately after use.

Recap the bottle tightly and store within the recommended temperature range.

• Application Checklist
• Cleanse and dry eyelids.
• Use one sterile applicator per eye.
• Apply a small line of 0.03% solution to the upper eyelid margin once nightly.
• Dispose applicator and re‑cap the bottle.

Monitoring And Follow-Up

Track cosmetic changes and any adverse effects at 4, 8, and 16 weeks to assess progress and tolerability.

For glaucoma patients, continue regular intraocular pressure monitoring per ophthalmologist recommendations.

Keep a photo log to document lash length and to detect early pigmentation or unwanted hair changes beyond the treated margin.

Timepoint	What To Check
Week 4	Initial lash change and any early irritation
Week 8	Progress toward fullness and continued tolerance
Week 16	Optimal cosmetic effect and reassessment of ongoing use

Delivery Across United States

City	Region	Delivery Time
New York	Northeast	5-7 days
Los Angeles	West	5-7 days
Chicago	Midwest	5-7 days
Houston	South	5-7 days
Phoenix	West	5-7 days
Philadelphia	Northeast	5-7 days
San Antonio	South	5-7 days
San Diego	West	5-7 days
Dallas	South	5-7 days
San Jose	West	5-7 days
Austin	South	5-7 days
Jacksonville	Southeast	5-7 days